This report studies the global soft tissue repair market, with forecast to 2019. The soft tissue repair market is expected to reach $14.7 billion in 2019 from $10.3 billion in 2014, at a healthy CAGR of 7.5% from 2014 to 2019. Growth in this market is attributed to the increasing incidence of soft tissue injuries, increasing healthcare expenditure, lack of substitutes for soft tissue repair surgery, increasing aging population & obesity rate, and geographic expansion by leading players in emerging markets. However, the increasing cost of surgical procedures, the lack of reimbursement, and stringent regulatory requirements are curbing market growth to a certain extent.

The global soft tissue repair market is segmented by product, application, and region. This report also discusses key market drivers, restraints, opportunities, and challenges for this market and submarkets. The market, by products, is segmented into tissue patches/meshes, soft tissue fixation devices, and laparoscopic instruments.

North America, a major market for global soft tissue repair, occupied a major share in this market, closely followed by Europe. However, emerging countries in the Asia-Pacific region and the Rest of the World (Latin America) are expected to record strong growth during the forecast period. Countries like India, China, and Brazil will majorly drive market growth owing to rising investments by public and private players to provide improved healthcare services in these countries, the presence of a large patient population, and the focus of leading players on capturing growth opportunities in these markets.

Key players in this market include LifeCell Corporation (U.S.), Organogenesis (U.S.), C.R. Bard, Inc. (U.S.), Johnson & Johnson (U.S.), Covidien plc (Ireland), Arthrex Inc. (U.S.), Smith & Nephew plc (U.K.), Integra Lifesciences Corporation (U.S.), Wright Medical Technology (U.S.), and Stryker Corporation (U.S.).